Epic's CSO Dena Marinucci Named to Pharmavoice 100

PharmaVOICE has named Dena Marinucci, Ph.D. CSO of Epic Sciences, to the magazine's 2015 list of 100 outstanding professionals in the life-sciences industry.  Dena was chosen as part of the group of visionary entrepreneurs who recognized an opportunity to fill an industry need and are successfully leading their companies to new heights.

Every year, PharmaVOICE receives thousands of nominations from readers for the most influential corporate leaders, in their field. Candidates are selected based on their ability to inspire peers through their actions, as well as exhibiting strong leadership qualities, fearless and unique approaches to problems, and innovation in strategies, products and services.

Epic Sciences is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic’s mission is to enable the rapid and non-invasive detection of cellular, genetic and molecular changes in cancer throughout a patient’s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). 

Epic’s no cell left behind™ technology helps will help match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Epic Science’s goal is to commercialize our technology to increase the success rate of cancer drugs in clinical trials, and improve patient outcomes by providing physicians real-time information to guide treatment choices and change devastating disease into manageable conditions.

Read the full profile of Dena in the August issue of PharmaVoice.

Learn more about Epic's technology.